Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution

• Published in: BMC cancer Vol. 23; no. 1; pp. 1 - 984
• Main Authors: Chen, Danzhi, Wang, Qinchuan, Dong, Minjun, Chen, Fei, Huang, Aihua, Chen, Cong, Lu, Yi, Zhao, Wenhe, Wang, Linbo
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 16.10.2023; BioMed Central; BMC
• Subjects: Adjuvant treatment; Analysis; Breast cancer; Cancer; Cancer patients; Cancer therapies; Care and treatment; Chemotherapy; Complications and side effects; ErbB-2 protein; Gene amplification; Histology; Lymph nodes; Lymphatic system; Medical colleges; Medical prognosis; Medical research; Medicine, Experimental; Neoadjuvant therapy; Nomograms; Patient outcomes; Patients; Pertuzumab; Regression analysis; Surgery; Survival; Tumors; China
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-11505-x

Background Neoadjuvant chemotherapy (NAC) has been widely applied in operable breast cancer patients. This study aim to identify the predictive factors of overall survival(OS) and recurrence free survival (RFS) in breast cancer patients who received NAC from a single Chinese institution. Patients and Methods There were 646 patients recruited in this study. All the patients were treated at department of Surgical Oncology, Sir Run Run Shaw Hospital between February 25, 1999 and August 22, 2018. The relevant clinicopathological and follow-up data were collected retrospectively. RFS and OS were assessed using the Kaplan-Meier method. Multivariate Cox proportional hazards model was also employed. Multi-variate logistic regression model was simulated to predict pathologic complete response (pCR). Results In total, 118 patients (18.2%) achieved pCR during NAC. The 5-year OS was 94.6% versus 78.1% in patients with and without pCR, respectively (P < 0.001). The 5-year RFS was 95.3% and 72.7%, respectively (P < 0.001). No difference was detected among molecular subtypes of 5-year RFS in patients obtained pCR. Factors independently predicting RFS were HER2-positive subtype (hazard ratio(HR), 1.906; P = 0.004), triple-negative breast cancer (TNBC) (HR,2.079; P = 0.003), lymph node positive after NAC(HR,2.939; P < 0.001), pCR (HR, 0.396;P = 0.010), and clinical stage III (HR,2.950; P = 0.016). Multi-variate logistic regression model was simulated to predict the pCR rate after NAC, according to clinical stage, molecular subtype, ki-67, LVSI, treatment period and histology. In the ROC curve analysis, the AUC of the nomogram was 0.734 (95%CI,0.867-12.867). Conclusions Following NAC, we found that pCR positively correlated with prognosis and the molecular subtype was a prognostic factor.